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1. Introduction 
1.1 The dark side of the sun 
The genome of all living organisms is constantly threatened by a number of endogenous 
and exogenous DNA damaging agents. Such damage may disturb essential cellular 
processes, such as DNA replication and transcription, thereby resulting in double-strand 
breaks (referred to as ‘replication fork collapse’), which can lead to chromosomal aberrations 
and/or cell death, ultimately contributing to mutagenesis, early aging and tumorigenesis 
(Ciccia & Elledge, 2010). One of the most important exogenous sources of DNA damage is 
the ultraviolet radiation (UV) component of sunlight, since it is responsible for a wide range 
of biological effects, including alteration in the structure of biologically essential molecules, 
such as proteins and nucleic acids. Indeed, UV is one of the most effective and carcinogenic 
exogenous agents that act on DNA, threatening the genome integrity and affecting normal 
life processes in different aquatic and terrestrial organisms, ranging from prokaryotes to 
mammals (Rastogi et al., 2010). In addition, UV is the major etiologic agent in the 
development of human skin cancers (Narayanan et al., 2010). 
Sunlight is the primary UV source, whose spectrum is usually classified according to its 
wavelength in UVA (320-400 nm; lowest energy), UVB (280-320 nm) and UVC (200-280 nm; 
highest energy). Although these three UV bands are present in sunlight, the stratospheric 
ozone layer entirely blocks the UVC and most of UVB, thus the solar UV spectrum that 
reaches the Earth’s ground is composed by UVA and some UVB, even though ozone layer 
depletion can cause changes in this spectral distribution (Kuluncsics et al., 1999). 
The chemical nature and efficiency in the formation of DNA lesions greatly depend on the 
wavelength of the incident photons. Despite its lowest energy, UVA light can deeply 
penetrate into the cells, mostly damaging DNA by indirect effects caused by the generation 
of reactive oxygen species which may react with nitrogen bases, resulting in base alterations 
and breaks in the DNA molecule. On the other hand, UVB can be directly absorbed by DNA 
bases, producing two main types of DNA damage, the cyclobutane pyrimidine dimers 
(CPDs) and pyrimidine-pyrimidone-(6-4)-photoproducts (6-4PPs), both resulting from 
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covalent linkages between adjacent pyrimidines located on the same DNA strand, which 
leads to severe structural distortions in the DNA double helix. Interestingly, it has been 
recently demonstrated that UVA can also be directly absorbed by the DNA molecule, 
efficiently generating both CPDs and 6-4PPs (Schuch et al, 2009). 
CPDs correspond to the formation of a four-member ring structure involving carbons C5 
and C6 of both neighboring bases, whereas 6-4PPs are formed by a non-cyclic bond between 
C6 (of the 5’-end) and C4 (of the 3’-end) of the involved pyrimidines. Since those lesions 
induce strong distortions in the DNA molecule, they may lead to severe consequences to the 
cell if not properly removed, such as transcription arrest and replication blockage, thus 
disturbing cell metabolism, interfering with the cell cycle and, eventually, inducing cell 
death. DNA mutations can also result from misleading DNA processing. Long term 
consequences may include even more deleterious events, such as photoaging and cancer 
(Sinha & Häder, 2002; Narayanan et al., 2010; Rastogi et al., 2010). 
1.2 DNA repair of UV lesions and related human syndromes 
To ensure the maintenance of the genome integrity, several mechanisms that counteract 
DNA damage have emerged very early in evolution, including an intricate machinery of 
DNA repair, damage tolerance, and checkpoint pathways (Figure 1). 
 
 
Fig. 1. Main consequences of DNA damage. DNA damage can be induced by a variety of 
endogenous and exogenous agents. Several mechanisms, including an intricate machinery 
of DNA repair, damage tolerance, and checkpoint pathways, counteract DNA damage, 
aiming for the maintenance of genome stability, and guaranteeing normal cell proliferation. 
When these mechanisms fail, errors in DNA replication and/or aberrant chromosomal 
segregations take place, increasing mutagenesis and genetic instability and contributing to a 
higher risk of cancer development. Alternatively, these damages may disturb the 
transcription and/or cause replication blockage, leading to cell death , thus contributing to 
early aging. 
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The nucleotide excision repair (NER) is one of the most versatile and flexible DNA repair 
systems, removing a wide range of structurally unrelated DNA double-helix distorting 
lesions, including UV photoproducts, bulky chemical adducts, DNA-intrastrand crosslinks, 
and some forms of oxidatively generated damage by orchestrating the concerted action of 
over 30 proteins, including the seven that are functionally impaired in xeroderma 
pigmentosum  patients (XPA to XPG) (Costa et al., 2003; de Boer & Hoeijmakers, 2000). The 
NER pathway has been extensively studied at the molecular level in both prokaryotic and 
eukaryotic organisms. Depending on whether the damage is located in a transcriptionally 
active or inactive domain in the genome, its repair will be processed by one of two NER 
subpathways: global genome repair (GG-NER) or transcription-coupled repair (TC-NER). 
Indeed, while GG-NER is a random process, removing distorting lesions over the entire 
genome, TC-NER focus on those lesions which block RNA polymerases elongation, thus 
being highly specific and efficient (Fousteri & Mullenders, 2008; Hanawalt, 2002). 
Briefly, the NER pathway involves a sequential cascade of events that starts with damage 
recognition, which defines the major difference between GG-NER and TC-NER. The latter is 
triggered upon blockage of RNA polymerase translocation at the DNA damage site, 
whereas GG-NER is evoked by specialized damage recognition factors, including the XPC-
hHR23B heterodimer, and also XPE for certain lesions. The subsequent steps are carried out 
by a common set of NER factors that are shared by both subpathways and involve opening 
of the DNA helix around the lesion site by the concerted action of two helicases; dual 
incision of the damaged strand at both sides of the lesion by two endonucleases; removal of 
the damaged oligonucleotide (24-32 mer); gap filling of the excised patch using the 
undamaged strand as a template by the action of the replication machinery; and ligation of 
the new fragment to the chromatin by DNA ligase (Cleaver et al., 2009; Costa et al., 2003). 
Even though the core NER proteins that carry out damage recognition, excision, and repair 
reactions have been identified and extensively characterized, the regulatory pathways which 
govern the threshold levels of NER have not been fully elucidated (Liu et al., 2010). A 
schematic representation of this repair mechanism in humans is illustrated in Figure 2. 
Several human autosomal recessive diseases are caused by dysfunction of the NER 
pathway, xeroderma pigmentosum (XP) being the prototype. Although this chapter will 
mainly focus on the XP syndrome, deficiencies in NER can also lead to other genetic 
diseases, such as trichothiodystrophy (TTD), Cockayne syndrome (CS), cerebro–oculo–
facial–skeletal syndrome (COFS) and UV-sensitive syndrome (UVsS), all of which have 
photosensitivity as a common feature. 
Xeroderma pigmentosum (XP) is a rare human disorder transmitted in an autosomal 
recessive fashion characterized by severe UV light photosensitivity, pigmentary changes, 
premature skin aging and a greater than 1,000-fold increase incidence of skin and mucous 
membrane cancer, including squamous and basal cell carcinomas and melanomas, with a 
30-year reduction in life span (Cleaver et al., 2009; Karalis et al., 2011; Narayanan et al., 
2010). In addition to cutaneous features, patients often develop ocular abnormalities, 
including neoplasms which may cause blindness. For most patients, often referred to as 
classical XP, this syndrome is caused by an impaired GG-NER activity, with or without 
deficiencies in TC-NER, determined by mutations in one of seven NER genes (XPA to XPG). 
When TC-NER is also affected (mutations in XPA, XPB, XPD and XPG genes), accelerated 
neurodegeneration may also occur in a substantial number of patients, suggesting increased 
neuronal cell death due to accumulated endogenous damage (Gerstenblith et al., 2010; 
Hoeijmakers, 2009). The eighth complementation group corresponds to the XP-variant  
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Fig. 2. Schematic representation of repair of DNA lesions by nucleotide excision repair 
(NER). Depending on where the DNA damage is located in the genome, it will be processed 
by one of the two NER subpathways: the global genome repair (GG-NER) or the 
transcription-coupled repair (TC-NER), that basically differ in the lesion recognition step. 
Lesions occurring randomly in the genome are recognized by the XPC-HR23B complex, 
with the participation of XPE (DDB1-DDB2) for certain lesions, both complexes are GG-
NER-specific. On the other hand, lesions present in the transcribed strand of active genes 
that lead to the RNA polymerase arrest trigger the TC-NER subpathway, which involves the 
CSA and CSB proteins. The following steps are common to both subpathways. The DNA 
double helix around the lesion is opened by XPB and XPD (helicases belonging to the TFIIH 
complex) and the single strand region is stabilized by RPA, allowing damage verification by 
the XPA protein. The DNA around the damaged site is then cleaved by the XPF–ERCC1 and 
XPG endonucleases, excising an oligonucleotide of 24-32 mer, and this patch is 
resynthesized by the replication machinery using the undamaged strand as a template. 
Finally, the new fragment is sealed to the chromatin by the DNA ligase. 
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(XPV) patients, whose XP phenotype is related to mutations in the POLH gene, which 
encodes the translesion synthesis DNA polymerase eta responsible for the replication 
process on UV-irradiated DNA templates (Johnson et al., 1999; Masutani et al., 1999). 
A list of NER genes, which are related to XP syndrome, with their specific functions is given 
in Table 1. 
 
Gene Protein 
Protein size 
(A.A.) 
Function Pathway 
 
XPA 
 
XPA 273 
Interacts with RPA and other NER 
proteins, stabilizing ssDNA regions 
and also facilitating the repair 
complex assembly. 
GG-NER 
TC-NER 
XPB XPB 782 
Belongs to TFIIH complex, working 
as a 3` → 5` helicase. 
GG-NER 
TC-NER 
XPC XPC 940 
Responsible for lesion recognition in 
GG-NER. 
GG-NER 
XPD XPD 760 
Belongs to the TFIIH complex, 
working as a 5` → 3` helicase. 
GG-NER 
TC-NER 
DDB2 
XPE/p48 
subunit 
428 
Forms a complex with XPE/p127 
subunit, which is believed to facilitate 
the identification of lesions that are 
poorly recognized by XPC-hHR23B. 
GG-NER 
XPF XPF 905 
Found as a complex with ERCC1, 
which functions as an endonuclease 
5’ of the lesion. 
GG-NER 
TC-NER 
XPG XPG 1186 
Functions as an endonuclease 3’ of 
the lesion. 
GG-NER 
TC-NER 
 
*GG-NER- global genome repair; TC-NER- transcription-coupled repair. 
Table 1. List of NER genes related to xeroderma pigmentosum and their roles in human 
DNA repair. 
The Cockayne syndrome (CS) is predominantly a developmental and neurological disorder, 
caused by mutations leading to a defective TC-NER, which prevents recovery from blocked 
transcription after DNA damage. CS patients are characterized by early growth and 
development cessation, severe and progressive neurodysfunction associated with 
demyelination, sensorineural hearing loss, cataracts, cachexia, and frailty (Weidenheim et 
al., 2009). Curiously, although severe photosensitivity is a common feature reported for 
most CS patients, it is not linked to an increased frequency of skin cancers, like it is in XP 
patients. Interestingly, specific mutations in one of three XP genes (XPB, XPD and XPG) 
may result in a clinical phenotype which reflects a combination of the traits associated with 
XP and CS (XP/CS patients). This observation indicates that simultaneous defects in GG-
NER and TC-NER can cause mutagenesis and cancer in some tissues and accelerated cell 
death and premature aging in others (Hoeijmakers, 2009). 
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The hallmark of trichothiodystrophy (TTD) is sulfur-deficient brittle hair, caused by a 
greatly reduced content of cysteine-rich matrix proteins in the hair shafts. In severe cases, 
mental abilities are also affected. Abnormal characteristics at birth and pregnancy 
complications are also common features of TTD, which may imply a role for DNA repair 
genes in normal fetal development (Stefanini et al., 2010). As CS patients, TTD patients do 
not present a high incidence of skin cancers. Genetically, three genes were identified for this 
disease (XPB, XPD and TTDA), but most TTD patients exhibit mutations on the two alleles 
of the XPD gene (Itin et al., 2001). 
Cerebro–oculo–facial–skeletal syndrome (COFS) is a disorder determined by mutations in 
CSB, XPD, XPG and ERCC1 genes, leading to a defective TC-NER (Suzumura & Arisaka, 
2010). It is characterized by congenital microcephaly, congenital cataracts and/or 
microphthalmia, arthrogryposis, severe developmental delay, an accentuated postnatal 
growth failure and facial dysmorphism. 
Photosensitivity and freckling are the main features of patients with UV-sensitive syndrome 
(UVsS), but these patients have mild symptoms and no neurological or developmental 
abnormalities or skin tumors. Although other genes may be involved, mutations in the CSB 
gene were found in some of these patients, leading to defective TC-NER of UV damage 
(Horibata et al., 2004; Spivak, 2005). 
Therefore, the general relationship between defects in NER genes and clinical disease 
phenotypes is complex, since mutations in several genes can cause the same phenotype, 
and different mutations in the same gene can cause different phenotypes (Kraemer  
et al., 2007). 
Even though DNA repair malfunctions are autosomal recessive diseases and their incidence 
is therefore relatively low (~1/100,000), many of the individuals with DNA repair 
deficiencies die in early childhood since there is no effective treatment, only palliative care. 
Therefore, the search for a long-term treatment has been intense. Several strategies using 
recombinant viral vectors are being used in order to improve the resistance of cells from 
these patients to DNA damaging agents (Lima-Bessa et al., 2009; Menck et al., 2007). Also, 
the studies of DNA repair mechanisms have yielded a better understanding of  specific cell 
processes which lead to human diseases such as cancer, neurodegeneration and aging 
(Hoeijmakers, 2009). This review will focus on the use of recombinant viral vectors for the 
purposes of investigating both the cellular responses to DNA damage and the perspectives 
of providing therapy for XP patients. 
2. Recombinant viral vectors as gene delivery tools 
An ideal gene delivery tool should have the ability to transduce proliferating and fully 
differentiated cells with high efficiency; mediate high-level, prolonged and controlled 
transgene expression; have little toxicity (both at cellular and organism levels); elicit small 
immune responses in vivo; and be able to accommodate large DNA fragments for transgene 
transduction (Howarth et al., 2010). Unfortunately, there is no single tool that fulfills all 
these criteria. 
Viruses have had million of years to improve their capacity to infect cells with the aid of 
evolutionary pressures. Researchers have been trying to take advantage of this ability 
creating recombinant viral vectors. In general, for that purpose, the viral genome is 
manipulated and sequences needed to form the infective virion are deleted, opening space 
to insert the transgene of interest. 
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Several viral vectors have been created and the most widely used are: adenovirus, retrovirus 
(including lentivirus) and adeno-associated virus. The main characteristics of these vectors 
are presented in Table 2. 
 
Virus Nucleic acid 
Genome 
size (Kb)
Envelope
Virion 
size 
(nm) 
Integration
Transgene 
size (Kb) 
Immune 
response 
Transgene 
expression 
Adenovirus dsDNA linear 36  90 episomal 8 - 25 *** 
days - 
months 
Adeno-
associated 
virus 
ssDNA linear 4.7  25 site-specific 4.7 - 9 * 
months-
years 
Retrovirus 
ssRNA 
(homodimer) 
7 - 12 * 100 random <10 ** years 
Lentivirus 
ssRNA 
(homodimer) 
9 * 100 random 10 - 16 ** years 
Table 2. Main features of viruses currently used as recombinant vectors for gene delivery. 
Searching for the perfect gene delivery tool, intense modifications have been added to the 
vectors’ genomes, nucleocapsid and envelopes, always searching for less immunogenic 
vectors, with higher and more specific transduction properties. Currently, recombinant 
viruses are the vector of choice for research and clinical trials worldwide, but still only few 
phase II or III trials are being conducted (Atkinson & Chalmers, 2010). All viral vectors cited 
here have already been used in in vitro, ex vivo and in vivo experiments and in clinical trials.  
2.1 Recombinant adenoviral vectors 
Adenoviruses (Ad) are non-enveloped double-stranded DNA viruses with tropism for the 
respiratory and ocular tissues. The first generation recombinant vector can carry up to 8 Kbp 
of DNA, while the last generation, in which the viral DNA sequence is completely deleted 
(also named gutless), is able to efficiently transduce over 25 Kbp of DNA (Atkinson & 
Chalmers, 2010). 
Despite the fact that the gutless vector needs the aid of helper viral proteins supplied in 
trans, adenoviral vectors are easily produced in high titers. Once the transgene has been 
delivered inside the nucleus it remains episomal, reducing the risk of tumorigenesis induced 
by insertional mutagenesis. On the other hand, the episomal DNA is not replicated and its 
segregation in mitosis leads to the eventual loss of the transgene in the daughter cells. Thus, 
the transgene expression is short-lived. A possible solution is to add a site-specific 
integration sequence next to the transgene, leading to a prolonged transgene expression 
(Atkinson & Chalmers, 2010). Another advantage of the adenoviral vectors is their ability to 
transduce post mitotic cells since the transgene is already delivered in its active form, as a 
double-stranded DNA. This property is of particular interest when aiming for gene therapy 
in neurons (Atkinson & Chalmers, 2010). 
The biggest challenge for the use of adenoviral vectors in vivo is the immunological response 
it elicits. This strong response is not only due to the natural immunogenicity of its 
components, but also to pre-existing immunity  caused by previous contact with at least one 
of the over 50 serotypes of human infecting adenovirus (Seregin & Amalfitano, 2009). 
Taking into consideration that these vectors are only capable of a transient expression of the 
transgene and that repeated dosage might be necessary, a strong immune response is very 
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undesirable. Possible alternatives to circumvent this issue are: manipulation of the viral 
capsid proteins and DNA, making them less immunogenic; the usage of a different serotype 
on each application; and the use of immunosuppressants (Atkinson & Chalmers, 2010; 
Seregin & Amalfitano, 2009). 
The great importance of the immunological response against a gene therapy vector was 
brought to attention when, in 1999, a patient suffering from an ornithine transcarbamylase 
deficiency, died due to an unexpected inflammatory response reaction to the adenoviral 
vector used in a clinical trial (Edelstein et al., 2007). Still, adenoviral vectors are currently the 
most widely used viral vectors in clinical trials, accounting for approximately 24% of all 
vectors used in gene therapy clinical trials (Edelstein et al., 2007; Hall et al., 2010). 
2.2 Recombinant adeno-associated viral (AAV) vectors 
Adeno-associated viruses (AAV) are non enveloped, single-stranded DNA, with serotype-
specific tropism viruses. To date, 12 serotypes have been identified in primate or human 
tissues (Schmidt et al., 2008) in a total of over 100 known serotypes (Wang et al., 2011). Their 
productive lytic infection depends on the presence of a helper virus, adeno or herpesvirus, 
that provide in trans the necessary genes for the AAV replication and virion production. In 
the absence of a helper virus, the AAV establishes its latent cycle integrating specifically in 
the 19q13.4 region of the human genome (Daya & Berns, 2008). The site-specific integration 
is mainly dependent on the virus internal terminal repeats (ITRs), the integration efficiency 
element (IEE) and Rep 68 and Rep 78 genes. In the 19q13.4 region, several muscle-related 
genes are present, including some responsible for actin organization. No significant side 
effects have been observed due to AAV genome integration in this chromosome region 
(Daya & Berns, 2008). 
The onset of transgene expression delivered by an AAV vector is delayed, usually starting 
several days after the transduction, probably due to the time invested in the synthesis of the 
DNA second strand (Michelfelder & Trepel, 2009). Although late, the transgene expression 
is long lasting and there is a very low humoral response, mainly related to previous 
exposure to the viral antigens (Daya & Berns, 2008). Despite the small size of the AAV 
nucleocapsid and genome, it has been shown that transgenes up to 7.2 Kb can be delivered 
by AAV vectors, but the oversized genomes reduce at least 10 fold the transduction 
efficiency (Dong et al., 2010). Several strategies have been developed seeking to optimize the 
vector capacity, such as the trans-splicing vector. With the simultaneous usage of two AAV 
vectors, this technology takes advantage of the concatamers formed by the ITRs that can 
recombine to form the desired transgene inside the transduced cell. These trans-splicing 
vectors allow the final transgene to have up to 9 Kb (Daya & Berns, 2008). 
Only recently adeno-associated viral vectors started being used in gene therapy research 
and account for less than 4% of all vectors used in gene therapy clinical trials (Edelstein et 
al., 2007; Hall et al., 2010). Although these vectors do not behave as the parental virus, since 
they do not integrate in the genome (due to the lack of the REP protein), gene expression can 
be very long and elicit low immunological responses, making AAV vectors promising in 
gene therapy investigations. 
2.3 Recombinant retroviral vectors 
The Retroviridae family is characterized by a single-stranded RNA genome which can only 
replicate inside the host cell with the aid of an RNA-dependent DNA polymerase, the 
reverse transcriptase. This enzyme transcribes the virus’ RNA into a DNA sequence that the 
host cell machinery can transcribe and translate (Froelich et al., 2010). 
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Retroviral vectors are capable of transducing a wide range of cell types, are able to 
accommodate extensive changes in their genome, accept long transgenes, have low 
immunogenicity, can be produced in high titers, and promote a prolonged transgene 
expression due to their ability to integrate into the host cell genome (Froelich et al., 2010).  
On the other hand, most retroviral vectors can only transduce replicating cells since the 
transport of the transcribed viral DNA to the nucleus is mitosis-dependent. Additionally, 
there is always the risk of insertional mutagenesis due to the semi-random integration of the 
vector genome in the host cell’s genome (Froelich et al., 2010). Nowadays, the most widely 
used retroviruses as gene therapy tools are the lentiviruses (LVs), such as the human 
immunodeficiency virus (HIV). These vectors have the same advantages as other retroviral 
vectors and are capable of transducing post mitotic cells. Moreover, the LVs tend not to 
integrate by transcription initiation sites, reducing the risk of insertional tumorigenesis 
(Froelich et al., 2010). 
The retroviral vectors were the first vectors used in gene therapy clinical trials in 1989 
(Edelstein et al., 2007, Rosenberg et al., 1990) and are extensively used in fundamental 
biological research, functional genomics and gene therapy (Mátrai et al., 2010). In 2004, 28% 
of the clinical trials involving viral vectors included retroviral vectors (Edelstein et al., 2007); 
in 2010 that number dropped to approximately 23% (Voigt et al., 2008). This drawback is 
due to the unfortunate events of the French severe combined immunodeficiency (SCID) trial 
in 2002, where two out of ten children died in consequence of a leukemia, which was related 
to the insertional mutagenesis of the retroviral vector used (Edelstein et al., 2007). 
Since then, special attention has been paid to the safety of these vectors as many are known 
to derive from viruses that cause severe diseases, such as the acquired immunodeficiency 
syndrome (AIDS). Strategies are constantly developed to prevent the risk of insertional 
mutagenesis. For that purpose, in addition to the virions being replication-defective, 
generated by trans-complementation, several further manipulations of the viral genome 
were made. The development of a self-inactivating (SIN) vector (Iwakuma et al., 1999) 
prevents horizontal and vertical gene transfer and diminishes the probability of the 
production of a replicating virion or over-expression of a host cell oncogene (Edelstein et al., 
2007). 
3. Investigating DNA damage responses with adenoviral vectors in  
human cells 
3.1 In vitro and in vivo adenoviral gene transduction for the correction of DNA  
repair defects 
The knowledge of the molecular defects in XP cells was the starting point for understanding 
how human cells handle lesions in their genome. So far, different techniques have been used 
to study DNA repair mechanisms and reverse malfunctions in this essential system. One 
powerful tool employed in these studies has been the use of recombinant adenoviral vectors 
to transduce DNA repair genes directly into human skin cells, aiming to improve the 
knowledge of basic mechanisms that cells use to protect their genome. 
Experiments using first generation recombinant adenoviral vectors have been successfully 
employed in the transduction of both SV40-transformed and primary fibroblasts derived 
from XP-A, XP-C, XP-D and XP-V patients (Armelini et al., 2007). The expression of the 
respective functional proteins in all transduced defective cell populations was significantly 
increased, reaching levels even higher than seen for wild type cells (Armelini et al., 2005; 
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Lima-Bessa et al., 2006; Muotri et al., 2002). Moreover, different phenotypical analyses, 
including cell cycle, apoptosis and cell survival assays, have been carried out, all indicating 
that the protein expression mediated by the recombinant adenoviruses was clearly 
accompanied by the recovery of the DNA repair ability and increased resistance to UV 
radiation, thereby demonstrating functional correction of the XP phenotype. It is worth 
mentioning that, even though transgene expression mediated by adenoviruses is typically 
short-lived, sustainable high expression of XPA and XPC proteins with parallel increased 
UV-irradiation resistance was obtained even two months after cell transduction (Muotri et 
al., 2002). 
For XP-A, XP-C and XP-D transduced cell lines, phenotypic analyses also involved assays 
aiming to investigate their ability to perform DNA repair after UV irradiation. This has been 
measured through determination of unscheduled DNA repair synthesis (UDS), which 
corresponds to the incorporation of [methyl-3H] thymidine in cells that are not in S-phase, 
and is visualized by autoradiography as the presence of radioactive grains inside nuclei. 
Interestingly, UDS activity in all transduced deficient cell lines was restored to levels 
comparable to NER proficient cell lines, indicating those cells became able to efficiently 
remove UV lesions by restoring NER activity. 
It is well known that UV radiation promotes DNA elongation delay as a result of replication 
blockage by UV photolesions (Cleaver et al., 1983), which can be easily seen by running 
pulse-chase experiments in alkaline sucrose gradients. Using this approach, it has been 
possible to show that XP-V transduced cells were able to elongate nascent DNA on UV-
damaged DNA templates as efficiently as wild type cells (Lima-Bessa et al., 2006), once 
again demonstrating the great potential of recombinant adenoviruses in the transduction 
and expression of functional proteins. 
One interesting conclusion came from the observation that even though XPA, XPC and XPD 
genes were over-expressed in all transduced cell lines when compared to NER proficient 
cells, this had no impact in the UV-resistance or NER capability, suggesting that neither of 
these proteins is limiting for NER in human cells. Another possible explanation is that once 
the NER pathway requires a coordinated action of several proteins, increasing only one of 
these proteins does not result in speeding up removal of the DNA lesions. Similarly, the 
excess of polη (XPV) mediated by adenoviral transduction has not affected cell survival nor 
elongation of replication products in UV-treated XP-A human cells, suggesting not only that 
polη is not a limiting factor for the efficient replication of the UV-damaged DNA in XP-A 
cells, but also demonstrating that the deleterious effects caused by the remaining DNA 
lesions in the genome cannot be mitigated by an efficient bypass mediated by polη. 
However, the potential of such vectors is not restricted to in vitro assays. Indeed, another 
real perspective is their use to investigate the molecular mechanisms of DNA repair and 
their consequences in vivo, thus opening new avenues for a better understanding of cellular 
and physiologic responses to DNA damage. In vivo experiments may also help to establish 
the relationship between DNA repair, cancer and aging, as mice models for different DNA 
repair syndromes have been developed by different groups worldwide. Despite the 
extensive use of these models to broaden the understanding of several DNA repair related 
disorders, little work has been done in vivo testing gene therapy strategies for these diseases. 
Indeed, up to the present moment, only one study showed an efficient in vivo gene therapy 
protocol for complementation of the XP phenotype (Marchetto et al., 2004). 
Exciting results by Marchetto and co-workers showed that the administration of 
subcutaneous injections of an adenoviral vector carrying the XPA human gene directly into 
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the dorsal region of XP-A knockout mice led to an extensive expression of the heterologous 
protein in different skin cells, including dermal fibroblasts, cells of the hair follicle and basal 
replicating keratinocytes, which are believed to be the starting point of most skin tumors. As 
a result, the repair capability of these transduced cells was restored, thus preventing UVB-
induced deleterious skin effects, such as persistent scars, skin hyperkeratosis and, 
ultimately, avoiding the formation of squamous cell carcinomas (Marchetto et al., 2004). 
Despite the promising results of this work, no others followed. Researchers are now aware 
of several possible limitations and complications of gene therapy after some unexpected 
severe events in clinical trials (Edelstein et al., 2007) and are spending more time improving 
gene targeting tools and techniques before risking in vivo approaches. In that sense, extreme 
progress has been made with experiments in vitro, as previously presented. A general panel 
showing the main uses of the recombinant adenoviral vectors carrying DNA repair genes is 
presented in Figure 3. 
 
 
Fig. 3. DNA repair gene transduction by recombinant adenoviruses. Adenoviral vectors 
have been successfully employed to transduce human XP genes directly into established 
human cell lines (left), XP knockout mice skin (center), and  fibroblasts  from the skin of XP 
patients (right ). Endpoints are indicated for each particular case. 
Based on the successful complementation of the XP phenotype both in vitro and in vivo, 
adenoviral vectors could be proposed as an efficient tool for diagnosis and identification of 
XP patients’ complementation groups. This hypothesis was recently tested and confirmed: 
with the use of adenoviruses carrying DNA repair genes, it has been possible to determine 
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the complementation group of three Brazilian XP patients, now characterized as XP-C 
patients. To that end, adenoviral transduced cells from these patients have been submitted 
to UV treatment and then analyzed by simple assays, such as cell survival and UDS (Leite et 
al., 2009). This diagnosis has been performed using the patients’ skin fibroblasts but the 
potential use of adenoviral vectors for this purpose becomes even more exciting, 
considering that the adenoviral transduction could be held in cells present in the patients’ 
blood, thus becoming a faster and less invasive technique. Besides scientific and 
epidemiological goals, the identification of the gene defect may help to predict clinical 
prognosis for the XP patients and guide appropriate genetic counseling for their families. 
Direct gene sequencing can be performed to identify the mutated genes, but as there are 
eight potential candidate genes for XP, functional complementation assays are still used for 
the genetic diagnosis of these patients.  
3.2 Investigating UV-induced cell responses employing photolyases 
Photoreactivation is a very efficient DNA repair mechanism, which specifically removes the 
two main UV photoproducts. Photoreactivation is carried out by flavoproteins known as 
photolyases. These enzymes recognize and specifically bind to UV lesions, thus reverting 
them back to the undamaged monomers, using a blue-light photon as energy source (Brettel 
& Byrdin, 2010; Sancar, 2008). Interestingly, photolyases demonstrate a great efficiency for 
discriminating the target lesion, either CPDs or 6-4PPs, and so far no photolyase has been 
shown to be able to repair both lesions. Thus, enzymes that repair CPDs are referred to as 
CPD-photolyases, while 6-4PP-photolyases specifically repair 6-4PPs (Müller & Carell, 
2009). Both classes of photolyases are evolutionarily related, but functionally distinct (Lucas-
Lledó & Lynch, 2009). Curiously, genes encoding genuine photolyases have been lost 
somehow in the course of the evolution of placental mammals, including humans. Instead, 
these organisms retain cryptochromes, photolyase-homologous proteins that participate in 
the maintenance of circadian rhythm, but that do not keep any residual activity related to 
DNA repair (Partch & Sancar, 2005). 
Previous studies have confirmed that the CPD-photolyase is active when delivered to 
human cells, reducing mutagenesis (You et al., 2001), preventing UV-induced apoptosis 
(Chiganças et al., 2000) and recovering RNA transcription driven by RNA polymerase II 
(Chiganças et al., 2002). These successful studies have motivated the adenoviruses-mediated 
expression of the CPD-photolyase from the rat kangaroo Potorous tridactylus and the plant  
6-4PP-photolyase from Arabidopsis thaliana in human cells aiming to discriminate the precise 
role of UV-induced cellular responses in both NER-deficient and NER-proficient human 
cells. Employing immunofluorescence, immunoblot and local UV experiments, it has been 
possible to see that these enzymes are not only very specific for their lesions, but are also 
really fast to find them, colocalizing with regions of damaged DNA and other DNA repair 
enzymes in less than two minutes (Chiganças et al., 2004; Lima-Bessa et al., 2008). 
Adenoviral-mediated photorepair of CPDs substantially prevented apoptosis in all UV-
irradiated cell lines (both NER-deficient and NER-proficient cells), confirming the 
involvement of these lesions in cell death signaling, as previously reported. On the other 
hand, 6-4PP repair by the 6-4PP-photolyase decreased UV-induced apoptosis only in those 
cell lines deficient for both NER subpathways, causing minimal effect, if any, in NER-
proficient cells, including those lacking polη. These results suggest that, when not efficiently 
repaired, 6-4PPs also have important biological consequences, triggering cell responses 
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leading to the activation of apoptotic cascades. Interestingly, in CS-A cells (TC-NER 
deficient), a substantial attenuation of apoptotic levels could be again detected when CPDs 
were removed from the genome by the means of CPD-photolyase, while no detectable effect 
was observed as a consequence of photorepair of 6-4PPs, indicating that CPD lesions are the 
major UV-induced DNA damage leading to cell death, also in cells that are only proficient in 
GG-NER, the main subpathway of NER responsible for the removal of 6-4PPs in humans 
(Lima-Bessa et al., 2008).  
These results suggest that CPDs and 6-4PPs may play different roles in UV-induced 
apoptosis depending on the repair capacity of human cells. In GG-NER proficient cells, the 
harmful effects of UV light seem to be predominantly due to the prolonged remaining CPDs 
in the genome caused by their slow removal by NER, with the minor participation of 6-4PPs 
(Lima-Bessa et al., 2008). Indeed, it has been reported that about 80–90% of 6-4PPs are 
removed from the human genome in the first 4 hours following UV exposure, whereas 40–
50% of CPDs still remain to be repaired 24 hours later, probably due to the higher affinity of 
the XPC/hHR23B complex for 6-4PPs (Kusumoto et al., 2001). Thus, the lack of noticeable 
effects on UV-induced apoptosis in NER-proficient cells after 6-4PPs photorepair may be 
simply due to their fast repair by GG-NER. On the other hand, as for CPDs, the remaining of 
6-4PPs in the genome seems to cause major disturbances in cell metabolism that lead to cell 
death. A summary of these results is shown in Figure 4. 
To further confirm the idea that the roles of CPDs and 6-4PPs in UV-killing are related to 
the cellular repair capacity, authors have expressed these photolyases in TTD1V1 cells, a 
particular TTD cell line with a slower kinetics of 6-4PPs repair, eliminating about 50% and 
70% of 6-4PPs at 6 and 24 hours post-UV treatment, respectively. Once again, repair of 
both lesions by the respective photolyase notably reduced apoptosis in these cells, even 
though the 6-4PP photorepair was less effective than seen for NER-deficient cell lines 
(Lima-Bessa et al., 2008). These photolyases were also used to identify a defect in the 
recruitment of downstream NER factors on certain XPD/TTD mutated cells, slowing 
down the removal of UV-induced lesions. As this recruitment was recovered by treatment 
with the histone deacetylase inhibitor trichostatin A, the data indicated that this defect is 
partially related to the accessibility of DNA damage in closed chromatin regions 
(Chiganças et al., 2008).  
Another interesting finding came from assays investigating the time-dependent kinetics of 
the apoptosis commitment after UV treatment. Transduced XP-A cells were UV-treated and 
photoreactivated (to allow photorepair of the respective UV lesions) at increasing periods of 
time. Surprisingly, the data suggests that the initial trigger event to cell death after UV 
irradiation is relatively delayed, since photorepair of CPDs or 6-4PPs was able to reduce 
apoptosis even when photoreactivation was performed up to 8 hours after UV irradiation. 
After that, photoreactivation did not prevent UV-killing in these cells, indicating a 
commitment by events that irreversibly lead to cell death. These results are also in 
agreement with the indications that fast removed lesions (such as 6-PPs) do not activate 
apoptosis in NER-proficient human cells (Lima-Bessa et al., 2008). The main implication of 
all these findings is the fact that skin carcinogenesis in XP patients may also have 6-4PP 
lesions as important players, suggesting that tumors from these individuals are not only 
quantitatively different from those of normal people, but may also have different causative 
lesions. Transduction of XP knockout mice with adenoviral vectors carrying photolyase 
genes may help to address this question. 
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Fig. 4. Effects of photorepair of CPDs and 6-4PPs on UV-induced apoptosis. (A) Summary of 
the impact of the specific removal of CPDs and 6-4PPs by photorepair in human cell lines 
with different DNA repair capabilities. (B) Schematic representation of the main conclusions 
of the results shown in panel A. Those results clearly implicate that CPDs and 6-4PPs play 
different roles on UV-induced apoptosis depending on the cellular repair capacity.  
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4. Employing retroviral vectors for correcting XP phenotype 
The first genetic analysis of XP patients was performed through somatic cell fusion followed 
by analysis of restoration of normal UDS. If somatic cell fusion complements XP genetic 
deficiency, it will then be positive for UDS activity. These experiments were able to identify the 
seven classical XP complementation groups and the variant group (Zeng et al., 1998). This 
implies that DNA repair deficiencies can, in fact, be corrected by the introduction of a normal 
copy of the affected gene, giving hope for the development of gene therapy protocols for XP 
patients. In fact, the introduction of a normal copy of the defective gene in XP cells can 
complement the DNA repair ability, as demonstrated by the delivery of conventional 
expression vectors, via calcium precipitation and microneedle injection (Mezzina et al., 1994). 
In 1995, viral vectors were first used as gene delivery tools in DNA repair experiments 
(Carreau et al., 1995a). In this study, a LXPDSN retroviral vector carrying the wild-type XPD 
gene was capable of complementing primary fibroblasts of XPD patients with a long-term 
expression. A subsequent study showed that this complementation was gene-specific and 
that there was a long-term expression of the transgene (Quilliet et al, 1996). The use of 
retroviral vectors for DNA repair genes delivery was further validated in 1996 and 1997, 
when XP-A, XP-B, XP-C and TTD-D cells were also complemented with the aid of gene-
specific retroviral vectors (Marionnet et al., 1996; Zeng et al., 1998). 
The compilation of these results shows that the retroviral delivery of several DNA repair 
genes was able to specifically complement several deficiencies presented by XP, CS and TTD 
patients such as UDS, reduced catalase activity, UV-sensitivity, recovery of RNA synthesis, 
increased mutation frequency, stabilization of p53 (Dumaz et al., 1998) and deregulation of 
ICAM-1 (Ahrens et al., 1997). 
Since XP patients already receive autologous graft transplants after massive skin tissue 
removal surgery (Atabay et al., 1991; Bell et al., 1983), most researches in the field of XP gene 
therapy focus on the three-dimensional skin reconstruction in vitro, using the patients’ cells 
genetically corrected ex vivo. In this technique, the patients’ fibroblasts and keratinocytes are 
cultured in vitro after a skin biopsy of a non-UV-irradiated area. Then, retroviral vectors are 
used to stably complement the genetic deficiency of these cells. Finally, the keratinocytes 
and the fibroblasts are used to three-dimensionally reconstruct the epidermis and dermis, 
respectively. This construct can then be used as a graft when the part of patient’s damaged 
skin is removed in a necessary surgery. To that end, Arnaudeau-Bégard and co-workers 
managed to complement XP-C keratinocytes, recovering a wild-type phenotype and UV-
resistance with the aid of a retroviral vector carrying a normal copy of the XPC gene 
(Arnaudeau-Bégard et al., 2003). Furthermore, Bergoglio and co-workers have also 
developed a selection method for genetically corrected keratinocytes that does not involve 
particles derived from microorganisms which could lead to immunological clearance of the 
transgene, using CD24 as an ectopic marker (Bergoglio et al., 2007). 
In 2005, Bernerd and co-workers were able to reconstruct a three-dimensional skin model in 
vitro using fibroblasts and keratinocytes from a donor XP-C patient. With this model, they 
were able to see that the XP skin has peculiar characteristics: hypoplastic horny layers, 
decreased and delayed keratinocyte differentiation, epidermal invaginations, a generally 
altered proliferation control and fibroblasts with distinct morphology and orientation. 
Furthermore, the epidermal invaginations were proven to be related to alterations of both 
keratinocytes’ and fibroblasts’ functions and were characterized as epidermoid carcinoma-
like structures (Bernerd et al., 2005). It is important to keep in mind that an XP skin biopsy 
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might give us further and more precise knowledge of the XP skin physiology, but this is a 
delicate procedure which requires the patients’ agreement.  
Since the use of common retroviral vectors in gene therapy can be dangerous due to semi-
random insertional mutagenesis, researchers have developed several self-inactivating-
lentiviral vectors carrying DNA repair genes. These vectors were shown to efficiently 
transduce primary and transformed fibroblasts, complementing in a gene-specific manner 
XP-A, XP-C and XP-D cells. Furthermore, the recovery of normal levels of UV-resistance in 
the transduced cells was shown to be persistent for at least 3 months (Marchetto et al., 2006). 
The reconstruction of a genetically corrected, three-dimensional XP skin followed by the 
implantation of the graft on a patient (Figure 5) is still an ongoing chore that has to be taken 
very cautiously, always prioritizing the patient’s well-being. 
 
 
Fig. 5. Schematic representation of ex vivo gene therapy for XP patients using recombinant 
retrovirus (Rt). Skin-derived fibroblasts and keratinocytes from an XP patient are cultivated 
in vitro, and transduced with retroviral vector carrying the wild type XP cDNA. Transduced 
cells are then used to reconstruct the human skin in vitro, with a normal phenotype. Dashed 
line raises the possibility of engraftment of the reconstructed skin directly on XP patients. 
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It is also important to keep in mind that these grafts do not include melanocytes, responsible 
for the very common melanomas in these patients (Khavari, 1998), and that the skin will 
only be genetically complemented in the areas that receive the grafts, all the other areas of 
the body will still be extremely photosensitive since no paracrine effect is known for DNA 
repair proteins and that immunological clearance or gene silencing by cellular methylation 
can always prohibit a long-term transgene expression (Magnaldo & Sarasin, 2002). 
Importantly, several XP complementation groups also present other relevant symptoms, 
such as neurodegeneration, which will not be improved by the skin grafts. For those 
patients, another kind of gene therapy might be more efficient, such as the development of 
genetically corrected stem cells (ESs) (Magnaldo & Sarasin, 2002) or induced pluripotent 
cells (iPSCs, see below (Alison, 2009). Unfortunately, there is still no reference on that kind 
of research for xeroderma pigmentosum. 
5. Host cell reactivation (HCR) as a tool for DNA repair research 
The host cell reactivation (HCR) technique was first described in human cells by Protic-
Sabljic and co-workers in 1985 (Protic-Sabljic et al., 1985). In this first work, the technique 
consisted of transducing cells with a plasmid containing a putative cDNA with a selective 
gene into XP cells to look for a reversion of the UV sensitivity due to gene complementation, 
allowing identification of the genes responsible for that phenotype.  
Other studies have refined the technique which is now widely used as an indirect measure 
of cellular DNA repair capacity. Mostly, a plasmid containing a reporter gene such as 
luciferase (LUC) or chloramphenicol acetyltransferse (CAT) is treated with a genotoxic agent 
such as UV radiation and introduced in the cell where DNA repair capacity is to be 
evaluated. If the cell is able to remove the lesions from the plasmid, the reporter gene will be 
expressed. Different DNA repair rates can be addresses by differences on the amount of 
gene reporter expression at a certain time (Merkle et al., 2004). A schematic representation of 
HCR is shown in Figure 6. 
 
 
Fig. 6. Schematic representation of host cell reactivation (HCR) assay. A plasmid carrying a 
reporter gene (in this case, the luciferase gene) is UV-irradiated in vitro and then transfected 
into host cells. 48 hours later, the cellular DNA repair capacity is indirectly estimated by 
measurement of the reporter gene activity in the cellular extract. 
In 1995, the HCR assay was further used to visualize the genetic complementation of 
mammalian expression vectors carrying the DNA repair genes XPA, XPB, XPC, XPD and 
CSB. In this study, plasmids containing LUC or CAT were UV irradiated and co-transfected 
with the plasmids containing each of the complementing genes of the DNA-repair deficient 
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cells. Again, only the cells with the correct complementation were capable of removing the 
DNA damage in the reporter gene, allowing the expression of that protein. This technique 
facilitates the identification of the complementation group of a given patient, being 
particularly useful in cases of CS, TTD and some XP patients such as XP-E that present a 
normal UDS after UV treatment (Carreau et al., 1995b).  
Recent data using the HCR assay has shown that the CS proteins are essential for the 
reversion of oxidated lesions (Pitsikas et al., 2005; Spivak & Hanawalt, 2006; Leach & 
Rainbow, 2011) and evidence obtained with HCR suggests that, unlike what was previously 
shown with UDS assays, DNA repair capacity in fibroblasts does not decrease with aging 
(Merkle et al., 2004). This reduction may however be cell type-specific and DNA repair 
pathway-specific since blood cells repair capacity decreases approximately 0.6% per year of 
age (Moriwaki et al., 1996). This technique is still widely used and its great advantage is that 
the DNA plasmids or the viral vectors are treated in a controlled manner, not being subject 
to the cell’s global response to the same treatment. Further technique improvements will 
surely allow HCR to be used in different assays such as in vivo, yielding a better knowledge 
of the DNA repair pathways and their interactions with other pathways and physiological 
events. 
6. Other treatments for xeroderma pigmentosum 
6.1 General care 
There is no treatment that has been proven so far to be 100% effective in all XP cases. The 
only palliative measure that patients can rely on is complete sun avoidance. This includes 
not only avoiding going out even on cloudy days and covering all exposed body areas such 
as skin and eyes, but also using special artificial lights that emit no UV wavelengths 
(Kraemer, 2008). Premalignant lesions, such as actinic keratoses, and malignant lesions must 
be quickly treated with topical 5-fluoracil or liquid nitrogen, imiquimod cream, 
electrodesiccation and curettage, surgical excision or chemosurgery, as needed. When 
extensive areas are damaged and have to be surgically removed, skin grafts from sun 
unexposed areas of the same patient should be used. When eyes are affected, 
methylcellulose eye drops or contact lenses can help prevent trauma and corneal 
transplantations might be needed in extreme cases (Kraemer, 2008). 
When caring for XP patients, it is very important to keep in mind that the total sun 
avoidance also prevents the production of vitamin D in the skin, so dietary supplementation 
might be needed. Furthermore, the DNA repair deficiencies which prevent the repair of 
photolesions may also make individuals sensitive to other mutagens such as cigarette 
smoke, so patients should be protected against these agents (Kraemer, 2008). 
Aside from removal of local lesions and total sun avoidance, two other palliative treatments 
might help improving the XP patient’s quality of life: topical use of T4 endonuclease (Yarosh 
et al., 2001) and oral intake of retinoids (Campbell & DiGiovanna, 2006). 
6.2 Topical use of T4 endonuclease 
In 1975, Tanaka and co-workers demonstrated that the bacteriophage T4 endonuclease V is 
capable of making an incision 5’ within a CPD lesion. The resulting DNA flap is recognized 
and removed by a 5’3’ exonuclease, leaving a gap that is filled by a DNA polymerase, 
using the undamaged single strand as a template. A DNA ligase then joins the repaired 
fragment to the parental DNA (Tanaka et al., 1975).  
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In the 80’s, Yarosh’s laboratory discovered that the T4 endonuclease V could be delivered 
into cells using 200 nm liposomes as a delivery vehicle. The anionic liposomes not only 
protect the cationic enzyme inside, but also promote the escape from a clatrin-coated 
endosome after cellular intake by destabilizing the vesicle’s membrane with an acid pH. By 
cleaving DNA at the site of UV-induced lesions, the enzyme reverses the DNA repair defect 
of XP cells (Yarosh, 2002). Further work by the same group also showed that these T4N5 
liposomes in a 1% hydrogel lotion when applied in cultured human fibroblasts, mouse 
dorsal back or cultured human breast skin is capable of delivering the enzyme into cells in 
less than one hour, being almost entirely restricted to the epidermis (Ceccoli et al., 1989; 
Kibitel et al., 1991). 
An inverse correlation was later shown between the T4N5 dose and the level of CPDs that 
remained in the epidermis. This curve reached a plateau (at 0.5 μg/ml), probably due to 
saturation of the cell machinery for further repairing the damage after the initial incision by 
the T4 enzyme (Yarosh et al., 1994). These studies also showed that even in the higher dose 
of T4N5 liposomes, only ~50% of the CPD lesions were removed but that was capable of 
reducing the mutagenesis rate by 99% in transformed fibroblasts and 30% in primary 
fibroblast cell culture. These numbers are probably not only related to the number of 
remaining lesions, but also to the smaller size of the repair patch filled by BER compared to 
that needed in NER (Yarosh, 2002; Cafardi & Elmets, 2008). 
Finally, after two phase I clinical trials (Yarosh et al., 1996 as cited in Cafardi & Elmets, 2008) 
and three phase II clinical trials (Wolf et al., 2000 and Yarosh et al., 1996 as cited in Cafardi & 
Elmets, 2008), in 2001 the T4N5 liposomes were tested in XP patients. The patients were 
instructed to apply 4-5 ml of the lotion containing 1 mg/ml of endonuclease everyday for a 
year. Except for lesion removal when necessary, and daily use of sunscreens of 15 SPF or 
higher, no concomitant treatments were allowed. The treatment was shown to be efficient, 
reducing the rate of actinic keratoses and basal-cell carcinomas to 68% and 30% respectively 
in the placebo and treatment groups, reducing tumor promotion and progression. The 
treatment was also capable of reducing some immunosuppressant molecules, such as 
interleukin-10 (IL-10) and tumor necrosis factor-α (TNF- α). Unfortunately, the treatment 
was only effective for patients under 18 years-old. This might be because XP patients older 
than that already had too much DNA damage in their cells that could not be reversed 
(Yarosh et al., 2001). Despite the promising results, there are currently no topical DNA 
repair enzymes approved by the FDA. Clinical trials are still being conducted to analyze the 
application of T4N5 liposomes in other deficiencies and immunosuppressed patients 
(Cafardi & Elmets, 2008). 
6.3 Oral use of retinoids 
Despite interventions such as sunlight avoidance and tumor removal, most of the XP 
patients continue to develop a large number of skin cancers. These high-risk patients may 
suffer from field cancerization that may happen when a wide field of the epithelium has 
been exposed to the same genotoxic agent and adjacent but not contiguous areas present 
genetic and morphological alterations that may lead to a carcinogenesis process. As the 
whole skin area has been exposed to sunlight, inducing independent tumors with different 
growth rates, this hypothesis may explain why the patients have a 30% increase in the 
chances of having a second basal cell carcinoma (BCC) and then a 50% increase of a third 
BCC (Campbell & DiGiovanna, 2006).  
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In XP patients, the oral use of retinoids might be beneficial, regardless of the strong side 
effects. In chemoprevention the goal is to identify early biological events in the epithelium 
which may lead to a carcinogenesis process and intervene with chemicals which will help 
stop or reverse the process (Campbell & DiGiovanna, 2006). Retinoids, also known as 
vitamin A, are the most studied chemopreventive agent for skin cancers, upper 
aerodigestive tract and breast and cervical cancers. The exact mechanisms through which 
the retinoids are capable of reducing cancer incidence are still unclear, but it has been 
shown that they are capable of altering keratinocytes’ growth, increasing their 
differentiation status, affecting their cell surface and immune modulation. Retinoids 
mediate gene transcription by binding to two families of nuclear receptors, the retinoid 
acid receptors (RARs) and the retinoid X receptors (RXRs). Retinoids have only a mild 
effect on existing tumors, but can suppress the development of new lesions (Campbell & 
DiGiovanna, 2006). In 1988, it was shown in a three year study that isotretinoin in a dose 
up to 2 mg/day/Kg was able to reduce skin cancers in XP patients by 63%. Unfortunately, 
in the year following the discontinuation of the treatment there was an increase of 8.5% of 
cancer incidence in those patients with reference to the two years of treatment (Kraemer et 
al., 1988). 
Furthermore, the constant use of retinoids can have severe side effects ranging from 
inflammation in existing tumors, dry skin and mucosa and hair loss to pancreatitis, 
osteoporosis, hyperostosis and myalgia among others. The retinoids’ toxicity is dose related 
and cumulative, but most of the side effects can be prevented with constant check-ups and 
use of local special moisturizers (Campbell & DiGiovanna, 2006). Indeed, several retinoids 
can be used as chemopreventives. The two most common are isotretinoin and acitretin, the 
first having a shorter half-life and being the drug of choice for women due to retinoids’ 
theratogenic potential, especially in fetuses (Campbell & DiGiovanna, 2006).  
6.4 Potential effects of DNA repair adjuvants 
The use of DNA repair adjuvants and antioxidants may also help reducing skin cancer 
incidence in XP patients. Some known DNA repair adjuvants are selenium, aquosum extract 
of Urcaria tomentosa and Interleukin-12 (IL-12) (Emanuel & Scheinfeld, 2007). 
Selenium seems to interact with Ref-1, activating p53, inducing the DNA repair branch of 
the p53 pathway, in a BRCA1-dependent manner, dealing mainly with oxidative stress 
(Fisher et al., 2006). On the other hand, it has been already reported that high levels of 
selenium can be mutagenic, carcinogenic and possibly teratogenic (Shamberger, 1985), 
probably due to non-specific sulfur substitution on proteins and consequent TC-NER 
activity decrease (Abul-Hassan et al., 2004). Thus, special attention should be taken 
regarding the dose of dietary selenium supplementation. 
The aquosum extract of Urcaria tomentosa (cat’s claw) seems to increase the removal of 
CPDs and reduce oxidative damage, either by an increase in base excision repair (BER) or 
by an antioxidant property, reducing erythema and blistering after UV. Despite several 
studies in vitro and in vivo, the precise mechanisms are still unknown (Emanuel & 
Scheinfeld, 2007). 
Another interesting finding is that, besides IL-12 being a strong immunomodulatory 
molecule, able to prevent UV-induced immunosuppression through IL-10 inhibition (de 
Gruijl, 2008), it is also capable of increasing DNA repair by inducing NER, as shown by the 
RNA level increase in some NER molecules (Schwarz et al., 2005). 
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6.5 Gene therapy targeted approaches: The use of meganucleases for correcting  
XP-C cells 
There are several techniques to specifically target, substitute, or correct a gene, diminishing 
the chances of insertional recombination, such as the use of recombinases, transposons, zinc-
finger nucleases, endonucleases and meganucleases (Silva et al., 2011). Meganucleases can 
function as RNA maturases, facilitating the maturation of their own intron or as specific 
endonucleases that can recognize and cleave the exon-exon junction sequence wherein their 
intron resides, creating a specific double strand break (DSB), giving rise to the moniker 
“homing endonuclease”. The meganuclease function is probably related to the current status 
of its lifecycle (Silva et al., 2011). 
Meganucleases can be used as gene targeting tools in several ways. Ideally, they can provide 
a true reversion of the mutation, but the efficacy of correction is invertionally correlated to 
the distance of the initial DNA DSB. Alternatively, it can insert a functional gene upstream 
of the mutated one or in a safe location where it will not induce insertional mutagenesis. 
Also, meganucleases can be used for introducing specific mutations for research purposes 
such as understanding the role of a gene or of a specific point mutation. Furthermore, 
meganucleases capable of targeting viral sequences are being researched as antiviral agents 
(Silva et al., 2011). 
Recently, the design of a specific I-CreI meganuclease targeting for the XPC gene was able to 
specifically target two XPC sequences, showing in vitro for the first time that extensive 
redesign of homing endonuclease can modify a specific chromosome region without lost of 
specificity or efficiency (Arnould et al., 2007). These results are very promising for the 
development of future gene therapy strategies for XP patients. 
6.6 Induced Pluripotent Cells (iPSCs) as gene therapy agents 
In 2006, the induction of pluripotent cells (iPSCs) by the expression of Oct3/4, Sox2, c-Myc 
and Klf4 in fibroblasts gave hope for a new gene therapy using pluripotent cells that would 
not elicit an immunological response in the patient, since his own cells would be used to 
induce the iPSCs and that would not be confronted by ethical issues like the use of 
embryonic stem cells (Takahashi & Yamanaka, 2006). Since then, this technology has been 
improved and iPSCs have been induced in a variety of cell types from different species. 
Also, iPSCs have been differentiated to several different cell types, from fibroblasts to 
neurons (Sidhu, 2011).  
Fanconi Anemina (FA) is a DNA repair related disease, where mutations in one of 
fourteen genes lead to extreme sensitivity to interstrand crosslinking agents. Patients 
show progressive bone marrow failure, congenital developmental abnormalities and early 
onset of cancers, mostly acute myelogenous leukemia and squamous cell carcinomas. 
Bone marrow transplantation is a palliative treatment for the secondary leukemia but no 
cure is currently available for FA patients (Kitao &.Takata, 2011). In 2009, Raya and co-
workers were able to use lentiviral vectors to genetically correct fibroblast and 
keratinocytes from patients with various FA complementation group deficiencies and 
then induce their dedifferentiation into pluripotent stem cells. Interestingly, uncorrected 
FA cells did not generate iPSCs, indicating a role for DNA repair in nuclear 
reprogramming. Thus, the generated iPSCs had normal FA genes and have the potential 
of being used for gene therapy of the donor patients, with no risk of inducing 
immunological rejection (Raya et al., 2009). Hopefully soon FA patients and others will be 
able to benefit from this technology as a safe gene therapy approach.  
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7. Concluding remarks 
Recombinant viral vectors were developed more than thirty years ago, and they have 
provided extremely useful tools to understand cell metabolism. This chapter focuses on 
their use to understand cells’ responses to DNA damage, especially UV-irradiated DNA 
repair-deficient cells. These vectors provide means to interfere in these responses, affecting 
DNA metabolism and revealing important aspects of the DNA repair mechanisms. The 
discovery of RNA interference mechanisms in human cells offer still more opportunities to 
modify cells’ responses by silencing specific DNA repair genes. Several libraries of viral 
vectors for the expression of small double-stranded RNA molecules (shRNA) targeting 
human genes are commercially available, and are already being used for understanding 
gene function. The use of such vectors to make cells deficient in more than one DNA repair 
pathway, using cells deficient in XP genes as hosts, for example, may help us to reveal the 
intricate network of interactions between the different metabolic pathways that contribute to 
genome maintenance after damage induction (Moraes, et al., 2011; in press). Moreover, the 
progress that has been made towards gene therapy for xeroderma pigmentosum, using 
these recombinant viral vectors is also discussed. Although the results indicate a series of 
limitations, and it is clear that there is still a long way to go, they make researchers go 
forward, giving a gleam of hope to these patients and their families. 
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